Companies /Healthcare
Jazz Pharmaceuticals plc
NASDAQ: JAZZ Biotechnology
$248.24
▲ $2.81 (+1.14%) today
Markets closed · 6:30pm ET

Jazz Pharmaceuticals (JAZZ) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
50%
EPS beat rate
−78.50%
Avg. EPS surprise
Consecutive EPS misses
JAZZ vs Market · 30-day return after each reportJAZZS&P 500
−9%0%+9%+18%+22.6%+2.5%Q2 25+21.0%+1.9%Q3 25−7.2%−8.5%Q4 25+1.5%+0.7%Q1 26−5.4%+0.2%Q2 26
−9%0%+9%+18%Q2 25Q3 25Q4 25Q1 26Q2 26
JAZZ EPS Trend · estimate vs actualEstimateActual
$-5$0$5$-6.25$-8.25Q2 25$5.85$8.13Q3 25$6.51$6.64Q4 25$4.66$6.34Q1 26$6.18$5.71Q2 26$0.95$-3.88Q3 26
$-5$0$5Q2 25Q4 25Q2 26
JAZZ Revenue Trend · estimate vs actualEstimateActual
$0$400.0M$800.0M$1.2B$1.0B$1.0BQ2 25$1.1B$1.1BQ3 25$1.2B$1.2BQ4 25$979.0M$1.1BQ1 26$1.1B$1.2BQ2 26$1.2B$1.2BQ3 26
$0$400.0M$800.0M$1.2BQ2 25Q4 25Q2 26

How Often Does Jazz Pharmaceuticals Beat Earnings Estimates?

Jazz Pharmaceuticals beat EPS estimates in 3 of its last 6 reported quarters, and has missed 2 quarters in a row.

JAZZ quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes acquired IPR&D expense of $754 million for ABS-1230 (JZP6979) from the Actio acquisition, impacting results by $11.32 per share (GAAP) and $11.03 per share (non-GAAP adjusted); GAAP results also include $34.2 million restructuring and other costs. $-3.88 est. $0.95 −508.59% $1.2B est. $1.2B +3.05%
Q2 2026 $5.71 est. $6.18 −7.54% $1.2B est. $1.1B +8.43%
Q1 2026 $6.34 est. $4.66 +36.18% $1.1B est. $979.0M +9.18%
Q4 2025 $6.64 est. $6.51 +2.05% $1.2B est. $1.2B +2.81%
Q3 2025 $8.13 est. $5.85 +38.97% $1.1B est. $1.1B +1.58%
Q2 2025 $-8.25 est. $-6.25 −32.07% $1.0B est. $1.0B −0.14%

Figures from SEC filings and company reports. Not investment advice.